Comparative Evaluation of Angiogenesis in Gastric Adenocarcinoma by Nestin and CD34

Kim, Hyung-Seok; Kang, Hun-Seok; Messam, Conrad A.; Min, Kyung-Whan; Park, Chang-Soo

doi:10.1097/00129039-200206000-00005

Cited by 28 publications

(27 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, nestin expression in endothelial cells that accompanied the process of angiogenesis has been reported (29)(30)(31)(32)(33). The nestin expression was specific to proliferative endothelium, and nestin regulates the proliferation of HUVEC cells.…”

Section: Introductionmentioning

confidence: 97%

Nestin as a novel therapeutic target for pancreatic cancer via tumor angiogenesis

Yamahatsu

Matsuda²,

Ishiwata

et al. 2012

Int J Oncol

View full text Add to dashboard Cite

Abstract. The class VI intermediate filament protein, nestin is reported to be a progenitor cell marker in various tissues. In the present study, we analyzed the expression and roles of nestin in angiogenesis of pancreatic ductal adenocarcinomas, and determined whether nestin is a potential target for inhibiting tumor angiogenesis using a gene silencing strategy. Nestin expression was detected only in small vessels, whereas CD34, CD31 and factor VIII were also expressed in large-sized blood vessels in PDAC. The number of nestin-positive vessels was approximately 20% the number of CD34-positive vessels, and the average dimension of nestin-positive vessels was approximately 75% that of CD34-positive vessels. The PCNA labeling indices of nestin-positive vessels were higher than those of CD34-positive vessels and nestin-negative vessels. Reducing nestin expression by use of siRNA targeting nestin transcripts inhibited growth of the vascular endothelial cell lines, but there was no difference in cell motility. In xenograft models, administration of siRNA targeting mouse-nestin suppressed subcutaneous human pancreatic cancer cell growth in nude mice. In conclusion, nestin was expressed in small proliferating blood vessels in pancreatic cancer tissues and may be a useful marker of angiogenesis in pancreatic ductal adenocarcinoma tissues. Furthermore, nestin is a potential novel therapeutic target in pancreatic cancers to inhibit tumor angiogenesis.

show abstract

Section: Introductionmentioning

confidence: 97%

Nestin as a novel therapeutic target for pancreatic cancer via tumor angiogenesis

Yamahatsu

Matsuda²,

Ishiwata

et al. 2012

Int J Oncol

View full text Add to dashboard Cite

show abstract

“…Surprisingly, no prognostic implications of nestin expression were found in glioblastoma multiforme, i.e., in the most malignant form of astrocytoma (52,53). In contrast, correlations between nestin expression and poorer clinical outcomes were documented in malignant melanoma (54), hepatocellular carcinoma (55), non-small cell lung carcinoma (56), gastric carcinoma (33) and prostate cancer (35).…”

Section: Discussionmentioning

confidence: 99%

“…Nestin expression has also been observed in various neoplasias, including gastrointestinal stromal tumors (26), brain tumors (27), prostate cancer (28), melanoma (29), osteosarcoma (30), dermatofibrosarcoma protuberans (31) and thyroid tumors (32). Furthermore, nestin is closely correlated with tumor angiogenesis, as it is also highly expressed in proliferating vascular endothelial cells (33)(34)(35). Additionally, nestin is widely considered to be a cancer stem cell marker in nervous system tumors (36)(37)(38), prostate cancer (39,40), pancreatic cancer (41), bladder cancer (42), and malignant rhabdoid tumors (43).…”

Section: Introductionmentioning

confidence: 99%

Nestin expression in high-grade osteosarcomas and its clinical significance

et al. 2012

View full text Add to dashboard Cite

Abstract. Nestin has been detected in various malignancies and its expression correlates with advanced grade in some neoplasms. The aim of this study was to examine nestin expression in high-grade osteosarcomas and to determine its prognostic value. Using immunohistochemistry and immunofluorescence, we evaluated nestin expression in tumor tissue samples from 45 patients with high-grade osteosarcomas. In both methods, the frequency of nestin-positive tumor cells was classified into three categories (1+, 2+ and 3+ for immunohistochemistry; 1F+, 2F+ and 3F+ for immunofluorescence) and clinicopathological correlations were statistically evaluated and analyzed. Nestin-positive tumor cells were detected in all of the examined osteosarcomas using both immunohistochemistry and immunofluorescence, although the proportion of undoubtedly positive neoplastic cells varied in individual samples from a few nestin-positive tumor cells to diffuse nestin positivity. High levels of nestin expression detected by immunofluorescence (2F+ and 3F+) were associated with worse clinical outcomes (OS, P=0.031; EFS, P<0.001). However, high levels of nestin expression as measured by immunohistochemistry trended towards shorter patient survival rates but did not reach statistical significance. Despite significantly shorter survival rates observed in patients with high levels of nestin expression assessed by immunofluorescence, nestin does not seem to represent a powerful prognostic marker that would be superior to conventional methods.

show abstract

“…Increased nestin expression has also been reported in various tumor cells, especially in central nervous system and gastrointestinal tumors as a poor prognostic factor (Eaker and Sallustio., 1994;Toshiyuki et al, 2011). High expression levels in tumor blood vessels and proliferating endothelial cells in certain tumor types suggest a relationship between tumor angiogenesis and nestin (Kim et al, 2002;Teranishi et al, 2007;Gravdal et al, 2009;Eaton et al, 2010). From urological point of view, reduction of nestin expression has been shown to be correlated with decreased invasion and migration capability of prostate cancer cells (Gravdal et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Nestin Expression in pT1 High-Grade Bladder Urothelial Carcinoma Patients Treated with Intravesical BCG

Şen

Bozkurt²,

Demir³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Possible roles of nestin expression in terms of predicting intravesical BCG therapy response in T1 high grade bladder cancer patients were investigated. Materials and Methods: T1 high grade bladder cancer patients who were treated with intravesical BCG between 1990-2009 were included. Immunohistochemical staining for nestin expression was performed. Nestin(+) and nestin(-) patients were compared in terms of recurrence and progression rates. Results: Sixty-three patients were included and median follow-up time was twenty-five months. After staining; 33 patients (52.4%) were classified as nestin (+) and 30 (47.6%) as (-). Nestin (+) patients were more likely to recur compared to nestin (-) patients (60.6% vs. 30%, p<0.05). Progression rates were also higher in nestin (+) patients, although this result did not reach statistical significance (15.2 % vs. 10 %, p=0.710). Conclusions: Nestin expression, which seems effective in predicting recurrence, appears to have a potential role in the urothelial carcinoma tumorigenesis. Patients with high grade bladder cancer and positive nestin expression need close follow-up and might be informed about more tendency to recur. Further comprehensive studies including larger patient cohorts may clarify the role of nestin in bladder cancer.

show abstract

Comparative Evaluation of Angiogenesis in Gastric Adenocarcinoma by Nestin and CD34

Cited by 28 publications

References 30 publications

Nestin as a novel therapeutic target for pancreatic cancer via tumor angiogenesis

Nestin as a novel therapeutic target for pancreatic cancer via tumor angiogenesis

Nestin expression in high-grade osteosarcomas and its clinical significance

Prognostic Significance of Nestin Expression in pT1 High-Grade Bladder Urothelial Carcinoma Patients Treated with Intravesical BCG

Contact Info

Product

Resources

About